全文获取类型
收费全文 | 528篇 |
免费 | 22篇 |
国内免费 | 96篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 33篇 |
基础医学 | 42篇 |
口腔科学 | 19篇 |
临床医学 | 104篇 |
内科学 | 138篇 |
皮肤病学 | 7篇 |
神经病学 | 7篇 |
特种医学 | 108篇 |
外科学 | 16篇 |
综合类 | 35篇 |
预防医学 | 24篇 |
眼科学 | 4篇 |
药学 | 80篇 |
肿瘤学 | 27篇 |
出版年
2023年 | 3篇 |
2022年 | 1篇 |
2021年 | 6篇 |
2020年 | 2篇 |
2019年 | 6篇 |
2018年 | 3篇 |
2017年 | 4篇 |
2016年 | 5篇 |
2015年 | 4篇 |
2014年 | 8篇 |
2013年 | 19篇 |
2012年 | 7篇 |
2011年 | 5篇 |
2010年 | 26篇 |
2009年 | 24篇 |
2008年 | 12篇 |
2007年 | 58篇 |
2006年 | 13篇 |
2005年 | 23篇 |
2004年 | 4篇 |
2003年 | 9篇 |
2002年 | 6篇 |
2001年 | 15篇 |
2000年 | 6篇 |
1999年 | 9篇 |
1998年 | 41篇 |
1997年 | 38篇 |
1996年 | 29篇 |
1995年 | 29篇 |
1994年 | 27篇 |
1993年 | 38篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 12篇 |
1989年 | 25篇 |
1988年 | 24篇 |
1987年 | 15篇 |
1986年 | 16篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 10篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1976年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有646条查询结果,搜索用时 0 毫秒
31.
An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction 总被引:1,自引:0,他引:1
Mulhall JP Bukofzer S Edmonds AL George M;Apomorphine SL Study Group 《Clinical therapeutics》2001,23(8):1260-1271
BACKGROUND: Because apomorphine is a dopamine agonist that acts on areas of the central nervous system believed to mediate penile erection, its use in erectile dysfunction (ED) has been investigated. However, it also produces nausea by dopamine-receptor stimulation of the chemotrigger zone in the brain. Therefore, a low plasma concentration, achieved rapidly, would be selective for the desired erectile response but would be below the dopamine threshold for nausea. OBJECTIVE: We evaluated the efficacy and tolerability of a dose-optimized regimen of a sublingual formulation of apomorphine (apomorphine SL) in the treatment of ED. METHODS: This was a multicenter, open-label, uncontrolled, Phase III dose-optimization study of apomorphine SL in heterosexual men with ED. The 2-week screening period, during which baseline severity of ED was determined using the International Index of Erectile Function, was followed by a 3-week dose-optimization period beginning at a dose of 2 mg. Patients were to make at least 2 attempts at intercourse per week throughout the study, placing 1 apomorphine tablet under the tongue beforehand. At the end of the first week, the dose could be increased to 3 mg at the discretion of the investigator; at the end of the second week, the dose could be increased to a maximum of 4 mg or decreased as needed. In the following 4-week treatment period, patients took their individual optimal doses. The primary efficacy variable was the percentage of attempts resulting in erections firm enough for intercourse, as assessed by investigators' review of data from patients' diaries. Secondary variables included the percentage of attempts resulting in successful intercourse, time to erection, and duration of erection. Information about adverse events, including their severity and relation to treatment, was determined on the basis of direct questioning, spontaneous reports, and review of patient diaries. RESULTS: The study enrolled 849 heterosexual men whose ages ranged from 31 to 78 years (mean, 58.1 years). They had a mean 5.7-year history of ED of varbus causes. ED was mild in 11.5% of the men, moderate in 23.8 c, and severe in 48.1%. When results of the last 8 attempts were pooled, representing the period during which patients were taking their optimal doses of apomorphine SL, the mean percentage of attempts resulting in erections firm enough for intercourse was 39.4%, compared with 13.1% at baseline; attempts resulting in intercourse increased from a mean of 12.7% at baseline to 38.3% with treatment. The average median time to erection was 23 minutes, and the average median duration of erection was 13 minutes. Nausea, the most common treatment-related adverse event (11.7%). was dose related and diminished with continued dosing. One patient had a single syncopal episode that was judged to be related to apomorphine SL. CONCLUSIONS: In the present study, a dose-optimization regimen of apomorphine SL-with dosing initiated at 2 mg and adjusted up to a maximum of 4 mg as needed-was effective and well tolerated in the treatment of ED, regardless of its cause or severity. 相似文献
32.
Background: An outbreak of food poisoning in a military establishment mess was investigated and remedial measures suggested. 相似文献
33.
高效液相色谱法测定寒痹停片中士的宁含量 总被引:6,自引:0,他引:6
目的:建立用HPLC测定寒痹停片中士的含量的方法。方法:氰基柱;流动相-甲醇-水-三乙胺-乙酸(9800:155:15:30);紫外检测波长254nm。结果:在4~20ug/ml范围内,标准曲线回归方程为:Y=-2803+8967x(r=0.9997),RSD=1.65%?加样回收率的平均值为99.82%。结论:实验表明,这是一个适用于生产控制和产品质量检验的简单、快速、准确的方法。 相似文献
34.
IS Park H Kiyomoto F Alvarez YC Xu HE Abboud SL Abboud 《American journal of kidney diseases》1998,32(6):1000-1010
The renal insulin-like growth factor-I (IGF-I) system has been implicated in the pathogenesis of renal hypertrophy, altered hemodynamics, and extracellular matrix expansion associated with early diabetes. The relative abundance of IGF binding proteins (IGFBPs) in the renal microenvironment may modulate IGF-I actions. However, the precise IGFBPs expressed in the glomerular and tubulointerstitial compartments during diabetic renal growth have not been characterized. In the present study, in situ hybridization studies were performed to examine the expression of IGFBP-1 to -6 messenger RNAs (mRNAs) 3, 7, and 14 days after streptozotocin (STZ) injection in rats. In control, nondiabetic kidneys, all six IGFBP mRNAs were differentially expressed with a predominance of IGFBP-5. The onset of renal hypertrophy in STZ-induced diabetes was associated with a rapid and site-specific induction of IGFBP-1, -3, and -5 mRNAs. In contrast, basal expression of IGFBP-2, -4, and -6 mRNAs was not altered in diabetic rats. IGFBP-5 mRNA expression increased in diabetic glomeruli, cortical, and inner medullary peritubular interstitial cells at days 3, 7, and 14. Although normal glomeruli failed to express IGFBP-3, it was induced concomitantly with IGFBP-5 in diabetic glomeruli and cortical peritubular interstitial cells. IGFBP-1 mRNA levels also increased in cortical tubular cells at each time point tested. Peak induction of IGFBP-3 and -5 was observed at day 3, whereas IGFBP-1 was delayed until day 7. IGFBP-1, -3, and -5 mRNA levels declined by day 14, but remained persistently elevated above control. By immunoperoxidase staining, similar alterations in the pattern of IGFBP-3 and -5 protein expression were observed at each time point. The preferential and site-specific increase in IGFBP-1, -3, and -5 suggest that these IGFBPs may regulate the local autocrine and/or paracrine actions of IGF-I and contribute to the pathogenesis of the early manifestations of diabetic nephropathy. 相似文献
35.
36.
37.
38.
39.
40.